Biotechnology major Biocon today said the US health regulator has completed inspection of its manufacturing plant in Vishakhapatnam without any observations.
The United States Food and Drug Administration (USFDA) inspected company's active pharmaceutical ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh from September 11 to 15, 2017, Biocon spokesperson said in a statement.
The audit was completed without any observations. "No form 483 was issued", it added.
A Form 483 is issued by the USFDA to notify a company's management of objectionable conditions at its manufacturing facilities. It is issued to the management of a firm at the conclusion of an inspection.
Shares of Biocon today closed at Rs 357.05 per scrip on BSE, up 2.94 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
